A randomized controlled trial on the effect of vitamin D3 on inflammation and cathelicidin gene expression in ulcerative colitis patients

Saudi Journal of Gastroenterology

Volumn 22, Issue 4, 2016, Pages 316-323

  Sharifi, Amrollah ^a   Hosseinzadeh Attar, Mohammad Javad ^a   Vahedi, Homayoon ^b   Nedjat, Saharnaz ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cathelicidin (hCAP18 LL37); ESR; hs CRP; inflammatory bowel disease; ulcerative colitis; Vitamin D

Indexed keywords

C REACTIVE PROTEIN; CALCIFEDIOL; CALCIUM; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; COLECALCIFEROL; HIGH SENSITIVITY C REACTIVE PROTEIN; PARATHYROID HORMONE; PLACEBO; UNCLASSIFIED DRUG; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE; VITAMIN;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PARALLEL DESIGN; PARATHYROID HORMONE BLOOD LEVEL; QUANTITATIVE ASSAY; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; ULCERATIVE COLITIS; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; BIOSYNTHESIS; BLOOD; COLITIS, ULCERATIVE; DIETARY SUPPLEMENT; DRUG EFFECTS; GENETICS; INTRAMUSCULAR DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED;

ADULT; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CATHELICIDINS; CHOLECALCIFEROL; COLITIS, ULCERATIVE; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; GENE EXPRESSION; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; VITAMINS;

EID: 84983744481     PISSN: 13193767     EISSN: 19984049     Source Type: Journal    
DOI: 10.4103/1319-3767.187606     Document Type: Article

References (44)

1. Carter MJ, Lobo AJ, Travis SP; IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 Suppl 5: V1-16
2. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140: 1785-94
3. Ho S, Pothoulakis C, Koon HW. Antimicrobial peptides and colitis. Curr Pharm Des 2013; 19: 40-7
4. Bals R, Wilson JM. Cathelicidins - A family of multifunctional antimicrobial peptides. Cell Mol Life Sci 2003; 60: 711-20
5. Schauber J, Iffland K, Frisch S, Kudlich T, Schmausser B, Eck M, et al. Histone-deacetylase inhibitors induce the cathelicidin LL-37 in gastrointestinal cells. Mol Immunol 2004; 41: 847-54
6. Schauber J, Rieger D, Weiler F, Wehkamp J, Eck M, Fellermann K, et al. Heterogeneous expression of human cathelicidin hCAP18/ LL-37 in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2006; 18: 615-21
7. Koon HW, Shih DQ, Chen J, Bakirtzi K, Hing TC, Law I, et al. Cathelicidin signaling via the Toll-like receptor protects against colitis in mice. Gastroenterology 2011; 141: 1852-63.e1-3
8. Wang TT, Dabbas B, Laperriere D, Bitton AJ, Soualhine H, Tavera-Mendoza LE, et al. Direct and indirect induction by 1, 25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J Biol Chem 2010; 285: 2227-31
9. Weber G, Heilborn JD, Chamorro Jimenez CI, Hammarsjo A, Törmä H, Stahle M. Vitamin D induces the antimicrobial protein hCAP18 in human skin. J Invest Dermatol 2005; 124: 1080-2
10. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-81
11. Jones G. Pharmacokinetics of Vitamin D toxicity. Am J Clin Nutr 2008; 88: 582S-6S.
12. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006; 84: 18-28
13. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140: 1817-26.e2
14. Sadeghi K, Wessner B, Laggner U, Ploder M, Tamandl D, Friedl J, et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol 2006; 36: 361-70
15. Kamen DL, Tangpricha V. Vitamin D and molecular actions on the immune system: Modulation of innate and autoimmunity. J Mol Med (Berl) 2010; 88: 441-50
16. Raman M, Milestone AN, Walters JR, Hart AL, Ghosh S. Vitamin D and gastrointestinal diseases: Inflammatory bowel disease and colorectal cancer. Therap Adv Gastroenterol 2011; 4: 49-62
17. Owczarek D, Cibor D, Mach T. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), arginine, and 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha) level in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2010; 16: 52-7
18. Sakpal TV. Sample size estimation in clinical trial. Perspect Clin Res 2010; 1: 67-9
19. Ledderose C, Heyn J, Limbeck E, Kreth S. Selection of reliable reference genes for quantitative real-Time PCR in human T cells and neutrophils. BMC Res Notes 2011; 4: 427
20. Pereira F, Barbáchano A, Singh PK, Campbell MJ, Muñoz A, Larriba MJ. Vitamin D has wide regulatory effects on histone demethylase genes. Cell Cycle 2012; 11: 1081-9
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-Time quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods 2001; 25: 402-8
22. Aranow C. Vitamin D and the immune system. J Investig Med 2011; 59: 881-6
23. Carr I, Mayberry JF. The effects of migration on ulcerative colitis: A three-year prospective study among Europeans and first-and secondgeneration South Asians in Leicester (1991-1994). Am J Gastroenterol 1999; 94: 2918-22
24. Papi C, Festa V, Leandro G, Moretti A, Tanga M, Koch M, et al. Long-Term outcome of Crohns disease following corticosteroid-induced remission. Am J Gastroenterol 2007; 102: 814-9
25. Solem CA, Loftus EV Jr., Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 707-12
26. Ananthakrishnan AN, Cheng SC, Cai T, Cagan A, Gainer VS, Szolovits P, et al. Serum inflammatory markers and risk of colorectal cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014; 12: 1342-8.e1
27. Aleksandrova K, Jenab M, Boeing H, Jansen E, Bueno-de-Mesquita HB, Rinaldi S, et al. Circulating C-reactive protein concentrations and risks of colon and rectal cancer: A nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol 2010; 172: 407-18
28. Burstein E, Fearon ER. Colitis and cancer: A tale of inflammatory cells and their cytokines. J Clin Invest 2008; 118: 464-7
29. Oussalah A, Chevaux JB, Fay R, Sandborn WJ, Bigard MA, Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohns disease treated with combination therapy. Am J Gastroenterol 2010; 105: 1142-9
30. Veit LE, Maranda L, Fong J, Nwosu BU. The Vitamin D status in inflammatory bowel disease. PLoS One 2014; 9: e101583
31. Schauber J, Dorschner RA, Coda AB, Büchau AS, Liu PT, Kiken D, et al. Injury enhances TLR2 function and antimicrobial peptide expression through a Vitamin D-dependent mechanism. J Clin Invest 2007; 117: 803-11
32. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a Vitamin D-mediated human antimicrobial response. Science 2006; 311: 1770-3
33. Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, et al. Cutting edge: 1, 25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004; 173: 2909-12
34. Tai EK, Wong HP, Lam EK, Wu WK, Yu L, Koo MW, et al. Cathelicidin stimulates colonic mucus synthesis by up-regulating MUC1 and MUC2 expression through a mitogen-activated protein kinase pathway. J Cell Biochem 2008; 104: 251-8
35. Das M, Tomar N, Sreenivas V, Gupta N, Goswami R. Effect of Vitamin D supplementation on cathelicidin, IFN-?, IL-4 and Th1/Th2 transcription factors in young healthy females. Eur J Clin Nutr 2014; 68: 338-43
36. Hata TR, Kotol P, Jackson M, Nguyen M, Paik A, Udall D, et al. Administration of oral Vitamin D induces cathelicidin production in atopic individuals. J Allergy Clin Immunol 2008; 122: 829-31
37. Del Pinto R, Pietropaoli D, Chandar AK, Ferri C, Cominelli F. Association between inflammatory bowel disease and Vitamin D deficiency: A systematic review and meta-analysis. Inflamm Bowel Dis 2015; 21: 2708-17
38. Froicu M, Cantorna MT. Vitamin D and the Vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol 2007; 8: 5
39. Daniel C, Sartory NA, Zahn N, Radeke HH, Stein JM. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther 2008; 324: 23-33
40. Reich K, Madsen K, Foshaug RR, Fedorak RN, Kroeker KI. 184 high dose Vitamin D supplementation stimulates innate cytokine responses in patients with inflammatory bowel disease on infliximab. Gastroenterology 2014; 146(5): 48. [Abstract]
41. Narula N, Marshall JK. Management of inflammatory bowel disease with vitamin D: Beyond bone health. J Crohns Colitis 2012; 6: 397-404
42. Day AS, Lemberg DA, Messenger R, Woodhead HJ. High dose Vitamin D therapy in paediatric IBD. Gastroenterology 2011; 140 (5): 512. [Abstract]
43. Moon M, Song H, Hong HJ, Nam DW, Cha MY, Oh MS, et al. Vitamin D-binding protein interacts with Aß and suppresses As-mediated pathology. Cell Death Differ 2013; 20: 630-8
44. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011; 128: 1414-24